Symbols

VXRT(Delisted)

Vaxart·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Revenue Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VXRT

Vaxart, Inc.

A biotech company developing oral vaccines for infectious diseases and cancer

Industry

Established Date

Listing Date

12/11/1981

Exchange

NASDAQ Stock Exchange

Full-time Employees

105

Fiscal Year Ends

12-31

Website

www.vaxart.com

Security Type

Common stock

Office address

170 Harbor Way, Suite 300, South San Francisco, California 94080

Business

Introduction

Vaxart, Inc., is a company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antiviral drugs. Vaxart's oral vaccine is designed to generate a broad and long-lasting immune response, protect against a variety of infectious diseases, and can be used to treat chronic viral infections and cancer. Vaxart's oral vaccine is administered in convenient room temperature stable tablets, not by injection. Vaxart believes that the tablet vaccine is easier to distribute and take than the injection vaccine, and can significantly improve vaccination rates. Vaxart's development plans include oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV) and therapeutic vaccines for human papillomavirus (HPV). Through the acquisition of other companies, Vaxart has also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma acuminatum caused by HPV virus types 6 and 11.

Earnings Call

Q1/2025

Estimate EPS-0.07

Actual EPS-0.07

Estimate Revenue--

Actual Revenue20.88M

Vaxart's Q1 2025 Earnings Call: Unpacking Key Contradictions in COVID-19 and Norovirus Strategies

May 20,2025 01:39·
Earnings Decrypt

Company Financials

EPS

VXRT has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected -0.06, beating expectations. The chart below visualizes how VXRT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VXRT has released its 2025 Q1 earnings report, with revenue of 20.88M, reflecting a YoY change of 857.18%, and net profit of -15.59M, showing a YoY change of 36.15%. The Sankey diagram below clearly presents VXRT's revenue sources and cost distribution.